Jiangsu Hengrui Medicine
600276.SS
#594
Rank
S$54.83 B
Marketcap
S$8.26
Share price
0.90%
Change (1 day)
-33.29%
Change (1 year)
Jiangsu Hengrui Medicine Company Limited is a Chinese pharmaceutical company engaged in the R&D, manufacturing and sales of healthcare products, including antineoplastic drugs, angiomyocardiac drugs, drugs for surgery, contrast agents and antibiotics

Half-year Reports

Thumbnail Jiangsu Hengrui Medicine
 Half-year Report 2026-h1

Half-year Report 2026-h1

Language: English

View Half-year Report
Thumbnail Jiangsu Hengrui Medicine
 Half-year Report 2026-h1

Half-year Report 2026-h1

Language: Chinese

View Half-year Report
Thumbnail Jiangsu Hengrui Medicine
 Half-year Report 2025-h1

Half-year Report 2025-h1

Language: English

View Half-year Report
Thumbnail Jiangsu Hengrui Medicine
 Half-year Report 2025-h1

Half-year Report 2025-h1

Language: Chinese

View Half-year Report
Thumbnail Jiangsu Hengrui Medicine
 Half-year Report 2024-h1

Half-year Report 2024-h1

Language: Chinese

View Half-year Report
Thumbnail Jiangsu Hengrui Medicine
 Half-year Report 2023-h1

Half-year Report 2023-h1

Language: Chinese

View Half-year Report
Thumbnail Jiangsu Hengrui Medicine
 Half-year Report 2022-h1

Half-year Report 2022-h1

Language: Chinese

View Half-year Report
Thumbnail Jiangsu Hengrui Medicine
 Half-year Report 2021-h1

Half-year Report 2021-h1

Language: Chinese

View Half-year Report
Thumbnail Jiangsu Hengrui Medicine
 Half-year Report 2020-h1

Half-year Report 2020-h1

Language: Chinese

View Half-year Report
Thumbnail Jiangsu Hengrui Medicine
 Half-year Report 2019-h1

Half-year Report 2019-h1

Language: Chinese

View Half-year Report
Thumbnail Jiangsu Hengrui Medicine
 Half-year Report 2018-h1

Half-year Report 2018-h1

Language: Chinese

View Half-year Report
Thumbnail Jiangsu Hengrui Medicine
 Half-year Report 2017-h1

Half-year Report 2017-h1

Language: Chinese

View Half-year Report
Thumbnail Jiangsu Hengrui Medicine
 Half-year Report 2016-h1

Half-year Report 2016-h1

Language: Chinese

View Half-year Report